Charlie Nicholls, PhD

Global HEOR Business Partner
Sanofi

Poster(s):

• (352) Transportability to the EU Population of the Efficacy of Belumosudil Versus Best Available Therapy for the Treatment of Chronic Graft-Versus-Host Disease
  Wednesday, October 29, 2025